COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - share repurchase programme
19/08/2024
Bagsværd, Denmark, 19 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
LIXTE Biotechnology Provides Update On Recent Activities and Developments
19/08/2024
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in [...]
Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry
19/08/2024
Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics’ New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner [...]
Spectral AI Announces Podium Presentation at BBA / ISBI Joint Conference Assessing Burn Wound Severity Using Multispectral Imaging and Artificial Intelligence
19/08/2024
DALLAS, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
19/08/2024
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, [...]
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
19/08/2024
TORONTO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), [...]
Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain
19/08/2024
BOSTON and ATHENS, Ga., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the U.S. Patent and [...]
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
19/08/2024
Company showcases property-based design and optimization of orally bioavailable degraders targeting KAT2A/B NEWTON, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics , a biotechnology company focused on [...]
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
19/08/2024
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari [...]
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19/08/2024
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1 clinical trial in [...]
Assure Announces Further Extension of Exchange Offer Relating to its Convertible Notes
19/08/2024
DENVER, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (“Assure” or the “Company”) (OTC: IONM), today announced that it has extended the expiration date of its exchange offer (the “Offer”) relating to the [...]
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19/08/2024
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde ® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- [...]
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/08/2024
Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for [...]
Calibre Scientific Acquires Industrial Glassware, a U.S. Manufacturer and Provider of Laboratory Supplies and Consumables
19/08/2024
LOS ANGELES, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Industrial Glassware (the “Company”), a U.S.-based manufacturer of caps, glass vials, glass and plastic bottles [...]
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
19/08/2024
PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics, the BridgeBio [...]
Kraig Biocraft Laboratories Successfully Completes Third Commercial Spider Silk Production Cycle
19/08/2024
ANN ARBOR, Mich., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has completed the third commercial spider silk production [...]
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
19/08/2024
PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing [...]
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
19/08/2024
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
19/08/2024
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential [...]

Pages